|
|
|||||||||
CA: A Cancer Journal for Clinicians, Vol 47, Issue 2 70-92, Copyright © 1997 by American Cancer Society
J. M. Jessup, H. R. Menck, A. Fremgen and D. P. Winchester
In summary, the ability to decrease the mortality of colorectal carcinoma
is increasingly within the grasp of clinicians. With accurate family and
personal history, it is possible to estimate the risk of colorectal cancer
and initiate FOBT and colonoscopy where appropriate. In the future,
germline and even somatic genetic testing will further increase our ability
to diagnose cancers before they become widely invasive. As molecular
biology unravels the cause of what currently appears to be the majority of
sporadic cancers, it may be possible to characterize more colorectal
cancers that are caused by novel, as yet not recognized mutator genes.
Unfortunately, a set of patients is likely to exist who remain to be
diagnosed by symptoms caused by advanced cancer. The goal for the clinician
is to decrease this subset to as small a group as possible.
ARTICLES
Diagnosing colorectal carcinoma: clinical and molecular approaches
Department of Surgery at New England Deaconess Hospital, Boston, Massachusetts, USA.
This article has been cited by other articles:
![]() |
G. Ercolani, G. L. Grazi, M. Ravaioli, M. Cescon, A. Gardini, G. Varotti, M. Del Gaudio, B. Nardo, and A. Cavallari Liver Resection for Multiple Colorectal Metastases: Influence of Parenchymal Involvement and Total Tumor Volume, vs Number or Location, on Long-term Survival Arch Surg, October 1, 2002; 137(10): 1187 - 1192. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |